Connor, Clark & Lunn Investment Management (CC&L)
DNTH icon

Connor, Clark & Lunn Investment Management (CC&L)’s Dianthus Therapeutics DNTH Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,738
Closed -$29.9K – 1296
2022
Q4 		$29.9K Sell
4,738
-676
-12% -$12K ﹤0.01% 1161
2022
Q3 		$122K Buy
5,414
+3,338
+161% +$91.4K ﹤0.01% 1030
2022
Q2 		$40K Buy
+2,076
New +$51.3K ﹤0.01% 1012

Other funds holding DNTH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TG
TCW Group Los Angeles, California $14.9B AUM 46.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s DNTH Position: Q1 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Dianthus Therapeutics (DNTH) in Q1 2023, closing a stake of 4,738 shares — an estimated $29.9K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in DNTH in Q2 2022 and held it in 3 quarters. The position peaked at $122K in Q3 2022. 52 funds tracked by Wall St. Rank hold DNTH as of Q1 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Dianthus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 4,738 Dianthus Therapeutics shares in Q1 2023, an estimated $29.9K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Dianthus Therapeutics in Q2 2022 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Dianthus Therapeutics position peaked at $122K in Q3 2022.
  • 52 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2023, filed 10 May 2023.